Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service

ShireShire plc (LSE: SHP, NASDAQ: SHPG) today announced an innovative partnership with CrowdMed, a Web-based technology that harnesses "the wisdom of crowds" to solve difficult medical cases online. Starting January 1, 2016, CrowdMed will be offered as a pilot to US Shire employees and covered dependents.

CrowdMed aims to use the collective knowledge of medical professionals, medical students and other interested parties to help initially diagnose difficult-to-identify conditions or to provide patients with second opinions on their medical diagnoses. Using a patented crowdsourcing technology, CrowdMed has resolved over 1,200 real-world medical issues to date with an over 60% success rate*.

Shire believes digital health is a disruptive movement that is already creating opportunities to leverage technology in ways not previously possible to the benefit of patients, medical professionals, and caregivers. As a leading global biotech focused on rare diseases and specialty conditions, Shire embraces innovative ideas and partnerships to address unmet medical needs.

"This pilot program demonstrates Shire’s commitment to exploring novel ideas and services to improve the lives of our employees and their families," said Shire's Chief Information Office Karl Hick. "CrowdMed may be able to provide a valuable alternative source of information for those struggling with a health condition."

CrowdMed Founder and CEO, Jared Heyman, commented, "We look forward to working with Shire to provide crowdsourced medical answers to every employee who submits a case on CrowdMed."

About Shire
Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

About CrowdMed
CrowdMed,Inc. harnesses the wisdom of crowds to collaboratively solve even the world’s most difficult medical cases quickly and accurately online.

On CrowdMed, a patient with an unsolved medical mystery posts their case by answering a comprehensive set of medical questions, and uploading relevant diagnostic & imaging test results. Then members of CrowdMed's community of thousands of Medical Detectives select and collaborate on solving it using chat, discussion, and point allocation features. Meanwhile, an innovative prediction market system accurately identifies the most probable diagnoses and solutions.

The San Francisco-based startup has raised over $3M in venture capital to date from top-tier Silicon Valley venture funds, including NEA, Khosla Ventures, Andreessen Horowitz, Greylock Partners, SV Angel, and Y Combinator, to disrupt the $320B Medical Centers of Excellence market by providing vastly more accurate, timely, and cost-effective diagnoses online.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...